<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39462119</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>26</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Engineered protein subunit COVID19 vaccine is as immunogenic as nanoparticles in mouse and hamster models.</ArticleTitle><Pagination><StartPage>25528</StartPage><MedlinePgn>25528</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">25528</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-76377-y</ELocationID><Abstract><AbstractText>Initial studies on the immunogenicity of SARS-CoV-2 (CoV-2) S glycoprotein ("spike") as a protein subunit vaccine suggested sub-optimal efficacy in mammals. Although protein engineering efforts have produced CoV-2 spike protein sequences with greatly improved immunogenicity, additional strategies for improving the immunogenicity of CoV-2 protein subunit vaccines are scaffolding and the use of adjuvants. Comparisons of the effectiveness of engineered protein-only and engineered protein-nanoparticles vaccines have been rare. To explore this knowledge gap, we inoculated mice with two doses of either sequence-optimized trimeric spike protein or one of several sequence-optimized spike nanoparticles. We measured their immune response up to two months after the first dose. We also measured the immune response and protection against live virus in hamsters inoculated with either sequence-optimized trimeric spike protein or a liposome-based sequence-optimized spike nanoparticle. We found that in the presence of adjuvant, the antibody and neutralization titers elicited by spike-nanoparticles were not significantly greater than those elicited by spike-only in mice, even at doses as low as 0.1 µg/animal. Hamsters vaccinated with spike-only or spike-nanoparticles were equally protected from live virus one month after their first inoculation. These results suggest that sequence-optimized protein subunit vaccines in the form of individual prefusion-stabilized trimers can be as effective in improving immunogenicity as scaffolded forms.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matthews</LastName><ForeName>Melissa M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Molecular Cryo-Electron Microscopy Unit, Okinawa Institute of Science and Technology Graduate University (OIST), Onna-son, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Tae Gyun</ForeName><Initials>TG</Initials><AffiliationInfo><Affiliation>Molecular Cryo-Electron Microscopy Unit, Okinawa Institute of Science and Technology Graduate University (OIST), Onna-son, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Keon Young</ForeName><Initials>KY</Initials><AffiliationInfo><Affiliation>Molecular Cryo-Electron Microscopy Unit, Okinawa Institute of Science and Technology Graduate University (OIST), Onna-son, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meshcheryakov</LastName><ForeName>Vladimir</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Molecular Cryo-Electron Microscopy Unit, Okinawa Institute of Science and Technology Graduate University (OIST), Onna-son, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iha</LastName><ForeName>Higor Alves</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Molecular Cryo-Electron Microscopy Unit, Okinawa Institute of Science and Technology Graduate University (OIST), Onna-son, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamai</LastName><ForeName>Miho</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Immune Signal Unit, Okinawa Institute of Science and Technology Graduate University (OIST), Onna-son, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasaki</LastName><ForeName>Daiki</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Immune Signal Unit, Okinawa Institute of Science and Technology Graduate University (OIST), Onna-son, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laurino</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Protein Engineering and Evolution Unit, Okinawa Institute of Science and Technology Graduate University (OIST), Onna-son, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toledo-Patiño</LastName><ForeName>Saacnicteh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Molecular Cryo-Electron Microscopy Unit, Okinawa Institute of Science and Technology Graduate University (OIST), Onna-son, Okinawa, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Protein Engineering and Evolution Unit, Okinawa Institute of Science and Technology Graduate University (OIST), Onna-son, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Office of the Provost, Okinawa Institute of Science and Technology Graduate University (OIST), Onna-son, Okinawa, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Tzung-Yang</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>Molecular Cryo-Electron Microscopy Unit, Okinawa Institute of Science and Technology Graduate University (OIST), Onna-son, Okinawa, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biological Chemistry, Academia Sinica, Nankang, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shibata</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Molecular Cryo-Electron Microscopy Unit, Okinawa Institute of Science and Technology Graduate University (OIST), Onna-son, Okinawa, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Bacteriology, Department of Microbiology and Immunology, Faculty of Medicine, Tottori University, Yonago, Tottori, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shibata</LastName><ForeName>Noriko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Molecular Cryo-Electron Microscopy Unit, Okinawa Institute of Science and Technology Graduate University (OIST), Onna-son, Okinawa, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Bacteriology, Department of Microbiology and Immunology, Faculty of Medicine, Tottori University, Yonago, Tottori, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obata</LastName><ForeName>Fumiko</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Bacteriology, Department of Microbiology and Immunology, Faculty of Medicine, Tottori University, Yonago, Tottori, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujii</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Bacteriology, Department of Microbiology and Immunology, Faculty of Medicine, Tottori University, Yonago, Tottori, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Toshihiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Joint Veterinary Medicine, Faculty of Agriculture, Tottori University, Tottori, Tottori, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Avian Zoonosis Research Center, Faculty of Agriculture, Tottori University, Tottori, Tottori, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Joint Veterinary Medicine, Faculty of Agriculture, Tottori University, Tottori, Tottori, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Avian Zoonosis Research Center, Faculty of Agriculture, Tottori University, Tottori, Tottori, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishikawa</LastName><ForeName>Hiroki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Immune Signal Unit, Okinawa Institute of Science and Technology Graduate University (OIST), Onna-son, Okinawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Molecular Cryo-Electron Microscopy Unit, Okinawa Institute of Science and Technology Graduate University (OIST), Onna-son, Okinawa, Japan. matthias.wolf@oist.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Biological Chemistry, Academia Sinica, Nankang, Taipei, Taiwan. matthias.wolf@oist.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JP18am0101076</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053758" MajorTopicYN="Y">Nanoparticles</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022223" MajorTopicYN="Y">Vaccines, Subunit</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015202" MajorTopicYN="N">Protein Engineering</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adjuvant</Keyword><Keyword MajorTopicYN="N">Nanoparticle</Keyword><Keyword MajorTopicYN="N">Protein engineering</Keyword><Keyword MajorTopicYN="N">Protein subunit vaccine</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 (CoV-2) spike protein</Keyword><Keyword MajorTopicYN="N">Scaffold</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>27</Day><Hour>7</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>27</Day><Hour>7</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>27</Day><Hour>0</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39462119</ArticleId><ArticleId IdType="pmc">PMC11512993</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-76377-y</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-76377-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature . 579, 265–269 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>DA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine. (2020). https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid</Citation></Reference><Reference><Citation>Heath, P. T. et al. Safety and Efficacy of NVX-CoV2373 Covid-19 vaccine. N. Engl. J. Med. 385, 1172–1183 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262625</ArticleId><ArticleId IdType="pubmed">34192426</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard, A. J. &amp; Bijker, E. M. A guide to vaccinology: from basic principles to new developments. Nat. Rev. Immunol. 21, 83–100 (2021). 10.1038/s41577-020-00479-7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7754704</ArticleId><ArticleId IdType="pubmed">33353987</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiley, D. C. &amp; Skehel, J. J. THE STRUCTURE AND FUNCTION OF TIlE HEMAGGLUTININ MEMBRANE GLYCOPROTEIN OF INFL1JENZA VIRUS. (1987). http://www.annualreviews.org</Citation><ArticleIdList><ArticleId IdType="pubmed">3304138</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier, S., Güthe, S., Kiefhaber, T. &amp; Grzesiek, S. Foldon, the natural trimerization domain of T4 fibritin, dissociates into a monomeric A-state form containing a stable β-hairpin: atomic details of trimer dissociation and local β-hairpin stability from residual dipolar couplings. J. Mol. Biol. 344, 1051–1069 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15544812</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl. Acad. Sci. U S A. 114, E7348–E7357 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5584442</ArticleId><ArticleId IdType="pubmed">28807998</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanat, F. et al. Introduction of two prolines and removal of the polybasic cleavage site lead to higher efficacy of a recombinant spike-based sars-cov-2 vaccine in the mouse model. mBio. 12, 1–10 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092267</ArticleId><ArticleId IdType="pubmed">33653892</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh, C. L. et al. Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge. Nat. Commun. 15, 1553 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10879192</ArticleId><ArticleId IdType="pubmed">38378768</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed, S. G., Orr, M. T. &amp; Fox, C. B. Key roles of adjuvants in modern vaccines. Nat. Med. 19, 1597–1608 (2013). 10.1038/nm.3409</Citation><ArticleIdList><ArticleId IdType="pubmed">24309663</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingale, J. et al. High-density array of Well-ordered HIV-1 spikes on synthetic liposomal nanoparticles efficiently activate B cells. Cell. Rep. 15, 1986–1999 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4889521</ArticleId><ArticleId IdType="pubmed">27210756</ArticleId></ArticleIdList></Reference><Reference><Citation>Bo, Y. &amp; Wang, H. Materials-based vaccines for infectious diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 14 (2022). 10.1002/wnan.1824</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9541041</ArticleId><ArticleId IdType="pubmed">35708013</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Director-General’s opening remarks at the media briefing – 5. May (2023). https://www.who.int/news-room/speeches/item/who-director-general-s-opening-remarks-at-the-media-briefing---5-may-2023 (2023).</Citation></Reference><Reference><Citation>Lu, M. et al. SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern. (2022). 10.1073/pnas</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9436349</ArticleId><ArticleId IdType="pubmed">35994646</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Kennedy, M. M. et al. Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits. Vaccine. 10.1016/j.vaccine.2023.02.050 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9968623</ArticleId><ArticleId IdType="pubmed">36868876</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Y. et al. A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike. (2022). 10.1073/pnas</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388148</ArticleId><ArticleId IdType="pubmed">35895717</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangaru, S. et al. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Sci. (1979). 370, 1089–1094 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857404</ArticleId><ArticleId IdType="pubmed">33082295</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen, A. A. et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7928838</ArticleId><ArticleId IdType="pubmed">33436524</ArticleId></ArticleIdList></Reference><Reference><Citation>Park, K. S. et al. Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2. J. Controll. Rel. 330, 529–539 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7749995</ArticleId><ArticleId IdType="pubmed">33358977</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, J. et al. Self-adjuvanting lipoprotein conjugate αgalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. J. Med. Chem. 65, 2558–2570 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35073081</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston, S. C. et al. A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model. Vaccines (Basel). 10, (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9145473</ArticleId><ArticleId IdType="pubmed">35632473</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimoto, T. et al. Induction of systemic, mucosal, and cellular immunity against SARS-CoV‐2 in mice vaccinated by trans‐airway with a S1 protein combined with a pulmonary surfactant‐derived adjuvant SF‐10. Influenza Other Respir Virus. 17, e13119 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9996429</ArticleId><ArticleId IdType="pubmed">36909295</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, Z. et al. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. Cell. Res. 32, 269–287 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8767042</ArticleId><ArticleId IdType="pubmed">35046518</ArticleId></ArticleIdList></Reference><Reference><Citation>Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell. 183, 1367–1382e17 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7604136</ArticleId><ArticleId IdType="pubmed">33160446</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, B. et al. A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. Sci. Rep. 10, 18149 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7584627</ArticleId><ArticleId IdType="pubmed">33097791</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Sci. (1979). 369, 1501–1505 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402631</ArticleId><ArticleId IdType="pubmed">32703906</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonhardt, F. et al. A systematic review about affinity tags for one-step purification and immobilization of recombinant proteins: integrated bioprocesses aiming both economic and environmental sustainability. 3 Biotech. 13, Preprintathttpsdoiorg101007s13205–Preprintathttpsdoiorg101007s13023 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10182917</ArticleId><ArticleId IdType="pubmed">37193330</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowe, J. et al. 6xHis-Ni-NTA chromatography as a superior technique in recombinant protein expression/purification (ed Harwood, A. J.) 371–387 (Humana, Totowa, NJ, 10.1385/0-89603-258-2:371. (1994).</Citation><ArticleIdList><ArticleId IdType="pubmed">7921034</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu, D. et al. Design of universal Ebola virus vaccine candidates via immunofocusing. Proc. Natl. Acad. Sci. U S A. 121 (7), e2316960121 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10873634</ArticleId><ArticleId IdType="pubmed">38319964</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, W. et al. Self-assembled ferritin-based nanoparticles elicit a robust broad-spectrum protective immune response against SARS-CoV-2 variants. Int. J. Biol. Macromol. 264, 130820 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38484812</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapia, D., Reyes-Sandoval, A. &amp; Sanchez-Villamil, J. I. Protein-based Nanoparticle Vaccine Approaches Against Infectious Diseases. Arch. Med.Res. 54, 168–175 (2023). 10.1016/j.arcmed.2023.02.003</Citation><ArticleIdList><ArticleId IdType="pubmed">36894463</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao, Y. et al. Hemagglutinin-based DNA vaccines containing trimeric self-assembling nanoparticles confer protection against influenza. J. Leukoc. Biol. 112, 547–556 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35040188</ArticleId></ArticleIdList></Reference><Reference><Citation>Adjuvanted Flu Vaccine. (2022). https://www.cdc.gov/flu/prevent/adjuvant.htm</Citation></Reference><Reference><Citation>Ott, G., Barchfeldj-, G. L. &amp; Van Nest, G. Enhancement of Humoral Response against Human Influenza Vaccine with the Simple Submicron Oil/Water Emulsion Adjuvant MF59. Vaccine. 13 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">8578842</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrapp, D. et al. Cryo-EM Structure of the 2019-NCoV Spike in the Prefusion Conformation. (2019). https://www.gisaid</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164637</ArticleId><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>Olia, A. S. et al. SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity. J. Biol. Chem. 297, 101127 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8393506</ArticleId><ArticleId IdType="pubmed">34461095</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao, H. C. et al. Low-dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased protective immunity. Int. J. Mol. Sci. 23 (9), 4902 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9101745</ArticleId><ArticleId IdType="pubmed">35563292</ArticleId></ArticleIdList></Reference><Reference><Citation>Avalos, A. M. &amp; Ploegh, H. L. Early BCR events and antigen capture, processing, and loading on MHC class II on B cells. Front. Immunol. 5 (2014). 10.3389/fimmu.2014.00092</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3948085</ArticleId><ArticleId IdType="pubmed">24653721</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff, M. F. A., Reid, B. &amp; James, K. Effect of antilymphocytic antibody and antibody fragments on human lymphocytes in vitro. Nature. 215, 591–594 (1967).</Citation><ArticleIdList><ArticleId IdType="pubmed">6050210</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodnow, C. C. et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. (1988).</Citation><ArticleIdList><ArticleId IdType="pubmed">3261841</ArticleId></ArticleIdList></Reference><Reference><Citation>Avalos, A. M. et al. Monovalent engagement of the BCR activates ovalbumin-specific transnuclear B cells. J. Exp. Med. 211, 365–379 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3920557</ArticleId><ArticleId IdType="pubmed">24493799</ArticleId></ArticleIdList></Reference><Reference><Citation>Minguet, S., Dopfer, E. P. &amp; Schamel, W. W. A. Low-valency, but not monovalent, antigens trigger the B-cell antigen receptor (BCR). Int. Immunol. 22, 205–212 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20145007</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkmann, C. et al. Molecular requirements of the B-cell antigen receptor for sensing monovalent antigens. EMBO J. 35, 2371–2381 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5090217</ArticleId><ArticleId IdType="pubmed">27634959</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafqat, A. et al. SARS-CoV-2 epitopes inform future vaccination strategies. Frontiers in Immunology vol. 13 Preprint at (2022). 10.3389/fimmu.2022.1041185</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9732895</ArticleId><ArticleId IdType="pubmed">36505475</ArticleId></ArticleIdList></Reference><Reference><Citation>Trevaskis, N. L., Kaminskas, L. M. &amp; Porter, C. J. H. From sewer to saviour-targeting the lymphatic system to promote drug exposure and activity. Nature Reviews Drug Discovery vol. 14 781–803 Preprint at (2015). 10.1038/nrd4608</Citation><ArticleIdList><ArticleId IdType="pubmed">26471369</ArticleId></ArticleIdList></Reference><Reference><Citation>Oussoren, C., Zuidema, J., Crommelin, D. J. A. &amp; Storm, G. Lymphatic uptake and Biodistribution of liposomes after Subcutaneous Injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochim. Biophys. Acta. 1328 (2), 261–272 (1997).</Citation><ArticleIdList><ArticleId IdType="pubmed">9315622</ArticleId></ArticleIdList></Reference><Reference><Citation>Veneziano, R. et al. Role of nanoscale antigen organization on B-cell activation probed using DNA origami. Nat. Nanotechnol. 15, 716–723 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7415668</ArticleId><ArticleId IdType="pubmed">32601450</ArticleId></ArticleIdList></Reference><Reference><Citation>La-Beck, N. M. &amp; Gabizon, A. A. Nanoparticle interactions with the immune system: clinical implications for liposome-based cancer chemotherapy. Front. Immunol. 8, 1-6 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5382151</ArticleId><ArticleId IdType="pubmed">28428790</ArticleId></ArticleIdList></Reference><Reference><Citation>Joyce, M. G. et al. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell. Rep. 37 (12), 110143 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8651551</ArticleId><ArticleId IdType="pubmed">34919799</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueda, G. et al. Tailored design of protein nanoparticle scaffolds for multivalent presentation of viral glycoprotein antigens. Elife. 9, 1–30 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402677</ArticleId><ArticleId IdType="pubmed">32748788</ArticleId></ArticleIdList></Reference><Reference><Citation>Akkaya, M., Kwak, K. &amp; Pierce, S. K. B cell memory: building two walls of protection against pathogens. Nat. Rev. Immunol. vol. 20 229–238 Preprint at (2020). 10.1038/s41577-019-0244-2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7223087</ArticleId><ArticleId IdType="pubmed">31836872</ArticleId></ArticleIdList></Reference><Reference><Citation>Gobeil, S. M. C. et al. D614G mutation alters SARS-CoV-2 Spike conformation and enhances protease cleavage at the S1/S2 Junction. Cell. Rep. 34 (2), 108630 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7762703</ArticleId><ArticleId IdType="pubmed">33417835</ArticleId></ArticleIdList></Reference><Reference><Citation>Costello, S. M. et al. The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes. Nat. Struct. Mol. Biol. 29, 229–238 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9007726</ArticleId><ArticleId IdType="pubmed">35236990</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanekiyo, M. et al. Rational design of an Epstein-Barr Virus Vaccine Targeting the receptor-binding site. Cell. 162, 1090–1100 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4757492</ArticleId><ArticleId IdType="pubmed">26279189</ArticleId></ArticleIdList></Reference><Reference><Citation>Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 26, 1033–1036 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8183627</ArticleId><ArticleId IdType="pubmed">32398876</ArticleId></ArticleIdList></Reference><Reference><Citation>Mozafari, M. R., Mazaheri, E. &amp; Dormiani, K. Simple equations pertaining to the particle number and surface area of metallic, polymeric, lipidic and vesicular nanocarriers. Sci. Pharm. 89 (2), 15 (2021).</Citation></Reference><Reference><Citation>Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods. 14, 331–332 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5494038</ArticleId><ArticleId IdType="pubmed">28250466</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, K. &amp; Gctf Real-time CTF determination and correction. J. Struct. Biol. 193, 1–12 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4711343</ArticleId><ArticleId IdType="pubmed">26592709</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. Elife. 7, e42166 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6250425</ArticleId><ArticleId IdType="pubmed">30412051</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuyama, S. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2- expressing cells. Proc. Natl. Acad. Sci. U S A. 117, 7001–7003 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7132130</ArticleId><ArticleId IdType="pubmed">32165541</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>